Cyprotex PLC Expansion of Drug Transporter Capabilities

TIDMCRX

Cyprotex PLC

09 October 2014

9 October 2014

Cyprotex PLC

Expansion of Drug Transporter Capabilities

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of its in-house drug transporter services. Cyprotex can now offer the full range of in vitro drug transporter assays that are recommended by the regulatory authorities in a high quality, robust, and timely manner.

Industry knowledge of drug transporters and how they influence drug interactions is growing rapidly. New regulatory guidance released by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2012, as well as a publication by the International Transporter Consortium in 2013, is guiding the future direction in this field. The regulatory authorities recommend screening those transporters which play a key role in potential clinical drug interactions using in vitro cell based assays. A range of transporters have now been implicated in clinical drug-drug interactions (including P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3 and OCT2), and this range will continue to expand as new research is published.

Recent investments in the transporter services offered at the Cyprotex site at Biohub Alderley Park include the purchase of a PerkinElmer MicroBeta(R) scintillation counter and a LabLogic Beta-RAM(R) . At this site, Cyprotex has gained a permit to store, handle and dispose of radiolabelled material which is essential for the transporter services and allows Cyprotex to expand their service offerings into new areas where use of radiolabelled material is important.

The drug transporter team at Cyprotex includes highly experienced scientists who have worked previously in the field of drug transporter research, adding to an already strong bioanalytical team which is well equipped with the latest technology for analysing a range of different chemistries. Robust sample analysis is an important stage in these studies, particularly for data submitted to the regulatory authorities.

Commenting on the launch of the new transporter facility, Dr Anthony Baxter, CEO of Cyprotex said: "Developing a transporter facility is critical to maintain our position as leaders in the ADME-Tox field. Cyprotex have created a centre of excellence in this area which combines highly experienced scientists with robust quality science and communication. Our comprehensive range of state-of-the-art bioanalytical equipment, knowledge and expertise in the bioanalytical field ensures that we have the best chance of detecting and analysing even the most challenging molecules. We will ensure that our range of assays in this area will continue to expand in line with regulatory guidance and customer demand."

For further information:

 
 Cyprotex PLC                                 Tel: [phone] 
                                               100 
 Dr Anthony Baxter, Chief Executive Officer   [e-mail] 
  John Dootson, Chief Financial Officer        www.cyprotex.com 
  Mark Warburton, Chief Operating Officer 
  and Legal Counsel 
 
 N+1 Singer (Nomad and broker to Cyprotex)    Tel: [phone] 
 Shaun Dobson                                 [e-mail] 
  Jen Boorer                                   [e-mail] 
                                               www.n1singer.com 
 
 FTI Consulting                               Tel: [phone] 
 Simon Conway                                 [e-mail] 
  Mo Noonan                                    www.fticonsulting.com 
 

Notes to Editors

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRALLFVEIDLTIIS